In the present paper, we characterized on-target effects of crizotinib by specifically evaluating its effects on ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) (which depends on ALK as a major oncogenic and trophic factor). The gene discussed is ALK; the disease is anaplastic large cell lymphoma.